Ovarian Cancer: Robyn's Survivor Story

Patient Info: Robyn Townsend

After surgery, 6 rounds of chemotherapy and ongoing olaparib, she reported no evidence of disease since the previous December.

MD AndersonRead more →

Targeted treatment for an 89-year-old woman with Stage IV HRD-positive ovarian cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: HRD-positive; germline BRCA2 pathogenic variant

Follow-up imaging showed a partial response, tumor markers improved, and she remained on treatment with better appetite and general condition at 7 months.

PubMed CentralRead more →

Stage II Ovarian Squamous Cell Carcinoma: Caitlin's Survivor Story

Patient Info: Caitlin Koehler, female, Under 40 | Stage II

Biomarkers: PD-L1: high expression

After surgery for recurrence, Caitlin remained on maintenance therapy and her follow-up scans showed no evidence of disease.

MD AndersonRead more →

Stage IV Ovarian Cancer First Found Through an Umbilical Metastasis

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: WT1-positive; CK7-positive; CA-125 321 U/mL at diagnosis

Metastatic Site: umbilicus

After 9 months of bevacizumab maintenance, her clinical and imaging findings remained stable.

PubMed CentralRead more →

Durable response after multiple treatments for ovarian clear cell cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HRD-positive; BRCA-negative; ARID1A mutation; PD-L1 CPS 30

She achieved a complete response, completed maintenance immunotherapy in May 2024, and continued anlotinib with normal follow-up imaging and tumor markers.

PubMed CentralRead more →

Ovarian Cancer Metastatic to an Axillary Lymph Node Without Breast Disease

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2 negative

Metastatic Site: right axillary lymph node

Secondary cytoreductive surgery in April 2025 achieved complete macroscopic cytoreduction, and she was discharged without complications.

PubMed CentralRead more →

Ovarian Cancer Remission With Olaparib After Chemotherapy Intolerance

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: germline BRCA1 mutation

At 48 months, imaging showed complete remission and CA125 was normal while she continued reduced-dose olaparib.

PubMed CentralRead more →

Stage IV Ovarian Cancer: Evelyn's Survivor Story

Patient Info: Evelyn, female | Stage IV

Biomarkers: HRD-positive

After chemotherapy and surgery, Evelyn reported an unremarkable final scan in May 2023 and then completed 2 years of Lynparza maintenance therapy guided by HRD-positive tumor testing.

Stage III Ovarian Cancer: Mary's Survivor Story

Patient Info: Mary Catherine Riley, Female, 40s | Stage III

After a 2023 recurrence, Mary achieved a complete response within 1 year on avutometinib and defactinib. She continues the approved combination with quarterly CT scans and monthly labs and has no evidence of disease.

Advanced high-grade serous ovarian cancer with treatment-resistant progression and hyperprolactinemia

Patient Info: Anonymized, Female, 50s

Biomarkers: BRCA1 variant of uncertain significance

The ovarian cancer continued to progress despite multiple treatments, and she died 2.5 years after the ovarian-cancer diagnosis.

PubMed CentralRead more →

Stage III BRCA1 Ovarian Cancer: Carla's Survivor Story

Patient Info: Carla Peoples, female | Stage III

Biomarkers: BRCA1 mutation

She was cancer-free after surgery and 6 rounds of chemotherapy and continued olaparib maintenance with CA-125 blood testing every 3 weeks.

MD AndersonRead more →

Ovarian Cancer Spreads to the Breast During Platinum-Resistant Recurrence

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2-negative; HRD-positive; PD-L1-positive; folate receptor alpha-positive

Metastatic Site: right breast, right axillary lymph nodes, cervical…

She remained alive with stable disease about 2 years after the breast metastasis was diagnosed while receiving seventh-line mirvetuximab-soravtansine.

PubMed CentralRead more →

BRCA1-Mutated Ovarian Cancer Responding to Niraparib After Olaparib Progression

Patient Info: Anonymized, Female, 60s

Biomarkers: Germline BRCA1 pathogenic variant c.188T>A; CA-125 4

Two months after starting niraparib, imaging showed a partial response and CA-125 normalized. At 15 months, she had achieved a complete response and remained progression-free while niraparib continued.

PubMed CentralRead more →

Stage III Ovarian Cancer: Jaclyn's Patient Story

Patient Info: Jaclyn (Jackie) VanRaaphorst | Stage III

Biomarkers: FRα-positive; CA-125 monitored

AACR later reported that Jackie died on January 16, 2025.

Stage I Ovarian Cancer: Elle's Patient Story

Patient Info: Elle Simone Scott, Female, Under 40 | Stage I

Living with recurrent ovarian cancer for more than 6 years after her September 2016 diagnosis, with an active clinical trial slowing progression at the May 2023 publication.

Dana-FarberRead more →

Stage IV Ovarian Cancer Complicated by Anti-Yo Cerebellar Degeneration

Patient Info: Anonymized, Female | Stage IV

Biomarkers: CA-125: 1767 kU/L; anti-Yo antibodies positive in serum and cerebrospinal fluid

Her anti-Yo paraneoplastic cerebellar degeneration progressed despite methylprednisolone and plasma exchange. Care became palliative, and she died 2 months after hospital admission.

PubMed CentralRead more →

Stage IIIC Ovarian Cancer Found During Preoperative Screening

Patient Info: Anonymized, Female | Stage III

Biomarkers: BRCA1 pathogenic variant on homologous recombination deficiency testing; germline BRCA1 pathogenic variant

At approximately 1 year after surgery, she was alive without evidence of recurrence while continuing olaparib and bevacizumab maintenance therapy.

PubMed CentralRead more →

Recurrent Malignant Ovarian Steroid Cell Tumor Treated With Multiple Therapies

Patient Info: Anonymized, Female

Biomarkers: PIK3CA, and ATM mutations; ER negative; PR negative

She experienced repeated pelvic and lung recurrences. Platinum-based treatment produced a complete PET-CT response and olaparib maintenance provided about 1 year without progression before a 5 mm lung recurrence was surgically removed.

PubMed CentralRead more →

Stage III Ovarian Cancer During Care for Common Variable Immunodeficiency

Patient Info: Anonymized, Female | Stage III

She remained alive on maintenance bevacizumab, with no radiologic evidence of ovarian-cancer progression.

PubMed CentralRead more →

Ovarian Cancer: Faye's Patient Story

Patient Info: Faye Belvin, Female

Faye was still receiving the trial combination and said the treatment was working and that she felt better than she had in the previous 2 years.

Recurrent Ovarian Cancer and Olaparib-Related Skin Toxicity

Patient Info: Anonymized, Female | Stage Metastatic/Advanced

Metastatic Site: peritoneum|liver

The latest chemotherapy was effective, and she was alive without signs of another recurrence at the last documented follow-up.

PubMed CentralRead more →

Stage III Ovarian Cancer: Karen's Survivor Story

Patient Info: Karen Howley LaCamera, 50s | Stage III

The REGN4018 clinical trial put Karen’s ovarian cancer into remission, which had lasted nearly a year when the story was written, with follow-up every 6 weeks.

Dana-FarberRead more →

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed CentralRead more →

MSI-High Malignant Struma Ovarii With Lung and Liver Metastases 17 Years Later

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRAS, and ATM mutations; Ki-67 approximately 15%–29%

Metastatic Site: lungs|liver

She remained asymptomatic and tolerated pembrolizumab without obvious adverse effects after 4 doses, with follow-up imaging planned for metastatic lung and liver disease.

PubMed CentralRead more →